ASCOLymphomas20/Presentations
TARGET AUDIENCE LEARNING OBJECTIVES
ACCREDITATION STATEMENT CREDIT DESIGNATION STATEMENT AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC) HOW TO USE THIS CME ACTIVITY CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Jeremy Abramson, MD Consulting Agreements: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene, Celgene Corporation, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, MorphoSys, Novartis; Contracted Research: Bristol-Myers Squibb Company, Seagen Inc. Christopher R Flowers, MD, MS Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, MEI Pharma Inc, Pharmacyclics LLC, an AbbVie Company, Spectrum Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas, Celgene Corporation, Eastern Cooperative Oncology Group, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, National Cancer Institute, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc, V Foundation for Cancer Research. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Seagen Inc and Verastem Inc. Release date: November 2020 |